特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
962858

がん免疫療法の世界市場の予測 (~2024年):タイプ (mAb (ネイキッド・結合型) ・がんワクチン・免疫チェックポイント阻害剤 (PD-1・PD-L1・CTLA-4))・用途(肺がん・黒色腫・白血病・リンパ腫)別

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024

出版日: | 発行: RNCOS E-Services Pvt. Ltd. | ページ情報: 英文 195 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.45円
がん免疫療法の世界市場の予測 (~2024年):タイプ (mAb (ネイキッド・結合型) ・がんワクチン・免疫チェックポイント阻害剤 (PD-1・PD-L1・CTLA-4))・用途(肺がん・黒色腫・白血病・リンパ腫)別
出版日: 2020年10月01日
発行: RNCOS E-Services Pvt. Ltd.
ページ情報: 英文 195 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界におけるがん免疫療法の市場規模は、2024年までに1350億米ドルへ達すると予測されています。地域別では、2019年に北米が最大のシェアを占めると推計されます。主要企業の存在、意識の向上およびより良い流通メカニズムは、北米が市場のリーダーとなる主な要因の一部となっています。

当レポートでは、世界のがん免疫療法市場について調査し、業界の成長に影響を及ぼす最新の動向・開発動向、主な促進要因と課題、機会、および主要な市販のがん免疫治療薬の売上高などについて分析しています。

目次

第1章 アナリストの見解

第2章 調査手法

第3章 がん免疫療法:概要

第4章 市場力学

  • 促進要因
    • がんの発生率の増加
    • 免疫チェックポイント阻害剤の売上高が市場の成長を促進
    • 高齢者人口の増加
    • 先進国における高額な医療費
    • 強力なパイプライン
    • 多種多様な適応症における有効性の向上
    • がん免疫治療製品の承認と採用の急増
  • 課題
    • ベストセラー薬剤の特許満了
    • 免疫療法治療後の副作用の数の増加
    • がん免疫療法の非常に高い開発コスト
    • 高額な治療費
    • 意識の欠如
  • 市場機会
    • オプジーボとキートルーダは大きな成長機会をもたらす
    • 併用療法は生存率の大幅な増加につながる可能性
    • CAR-T療法:がん治療の未来
    • 次世代免疫療法に大きなチャンスを提供する中小企業

第5章 世界のがん免疫療法市場の見通し

第6章 世界のがん免疫療法市場:製品クラス別

  • モノクローナル抗体(mAbs)
    • ネイキッドモノクローナル抗体
    • 結合型モノクローナル抗体
    • 二重特異性モノクローナル抗体
    • その他
  • 治療用ワクチン
    • Provenge
  • 免疫チェックポイント阻害剤
    • CTLA-4阻害剤(細胞傷害性Tリンパ球関連タンパク質-4)
    • PD-1およびPD-L1阻害剤(プログラム死1およびプログラム死リガンド
  • その他

第7章 世界のがん免疫療法市場:主な適応症別

  • 頭頸部がん
  • 肺がん
  • 黒色腫
  • リンパ腫
  • 白血病
  • その他

第8章 世界のがん免疫療法市場:地域別

  • 北米
  • 欧州
  • アジア太平洋

第9章 動向&開発

  • 有利な投資動向
  • 標的療法と併用療法の出現
  • IO市場への最大の貢献を示すNSCLCおよび黒色腫

第10章 がん免疫療法業界における戦略的コラボレーションとアライアンス

第11章 がん免疫療法のパイプライン分析

第12章 競合情勢

  • 主要企業のシェア

第13章 主要企業の分析

  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Novartis
  • AstraZeneca Plc
  • Pfizer Inc
  • Eli Lilly and Company
  • Johnson & Johnson
  • Amgen Inc.
図表

List of Figures:

  • Figure 4-1: Global - Cancer Incidences (Million), 2020, 2025, 2030, 2035 & 2040
  • Figure 4-2: Global - Cancer Mortality (Million) 2020, 2025, 2030, 2035 & 2040
  • Figure 4-3: Global - Population above 65 Years (Billion), 2019 & 2050
  • Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2018-2024
  • Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2019
  • Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2024
  • Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2018-2024
  • Figure 6-4: Global - Rituxan Market (Million US$), 2016-2019
  • Figure 6-5: Global - Avastin Market (Million US$), 2016-2019
  • Figure 6-6: Global - Herceptin Market (Million US$), 2016-2019
  • Figure 6-7: Global - ADCETRIS Market (Million US$), 2016-2019
  • Figure 6-8: Global - Kadcyla Market (Million US$), 2016-2019
  • Figure 6-9: Global - Blincyto Market (Million US$), 2016-2019
  • Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), 2018-2024
  • Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Million US$), 2018-2024
  • Figure 6-12: Global - Provenge Market (Million US$), 2016-2019
  • Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2018-2024
  • Figure 6-14: Global - Yervoy Market (Million US$), 2016-2019
  • Figure 6-15: Global - Opdivo Market (Million US$), 2016-2019
  • Figure 6-16: Global - Keytruda Market (Million US$), 2016-2019
  • Figure 6-17: Global - Others Immuno-oncology Drugs Market (Billion US$), 2018-2024
  • Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2019
  • Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2024
  • Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2018-2024
  • Figure 7-4: Head & Neck Cancer - Immunotherapy Clinical Studies by Product-class
  • Figure 7-5: Head & Neck Cancer - Immunotherapy Clinical Studies by Phase
  • Figure 7-6: Global - Lung Cancer Market (Billion US$), 2018-2024
  • Figure 7-7: Lung Cancer - Immunotherapy Clinical Studies by Product-class
  • Figure 7-8: Lung Cancer - Immunotherapy Clinical Studies by Phase
  • Figure 7-9: Global - Melanoma Market (Billion US$), 2018-2024
  • Figure 7-10: Melanoma - Immunotherapy Clinical Studies by Product-class
  • Figure 7-11: Melanoma - Immunotherapy Clinical Studies by Phase
  • Figure 7-12: Global - Lymphoma Market (Billion US$), 2018-2024
  • Figure 7-13: Lymphoma - Immunotherapy Clinical Studies by Product-class
  • Figure 7-14: Lymphoma - Immunotherapy Clinical Studies by Phase
  • Figure 7-15: Global - Leukemia Market (Billion US$), 2018-2024
  • Figure 7-16: Leukemia - Immunotherapy Clinical Studies by Product-class
  • Figure 7-17: Leukemia - Immunotherapy Clinical Studies by Phase
  • Figure 7-18: Global - Other Cancer Market (Billion US$), 2018-2024
  • Figure 7-19: Other Cancer - Immunotherapy Clinical Studies by Product-class
  • Figure 7-20: Other Cancer - Immunotherapy Clinical Studies by Phase
  • Figure 8-1: Global - Share of Immuno-Oncology Market by Geography (%), 2019
  • Figure 8-2: Global - Share of Immuno-Oncology Market by Geography (%), 2024
  • Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2018-2024
  • Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2018-2024
  • Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2018-2024
  • Figure 11-1: Global - Immuno-Oncology Clinical Studies by Product-class
  • Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2019
  • Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2019
  • Figure 13-1: F. Hoffmann-La Roche AG - Revenue by Business Segment (%), 2019
  • Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceutical Division Revenue by Geography (%), 2019
  • Figure 13-3: Bristol Myers Squibb - Revenue by Geography (%), 2019
  • Figure 13-4: Merck & Co., Inc. - Revenue by Business Segment (%), 2019
  • Figure 13-5: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segment (%), 2019
  • Figure 13-6: Merck & Co., Inc. - Revenue by Geography (%), 2019
  • Figure 13-7: Novartis - Revenue by Business Segment (%), 2019
  • Figure 13-8: Novartis - Innovative Medicines Division Revenue by Segment (%), 2019
  • Figure 13-9: Novartis - Pharmaceuticals Division Revenue by Segment (%), 2019
  • Figure 13-10: Novartis - Revenue by Geography (%), 2019
  • Figure 13-11: AstraZeneca Plc - Revenue by Business Segment (%), 2019
  • Figure 13-12: AstraZeneca Plc - Revenue by Geography (%), 2019
  • Figure 13-13: Pfizer Inc - Revenue by Business Segment (%), 2019
  • Figure 13-14: Pfizer Inc - Revenue by Geography (%), 2019
  • Figure 13-15: Eli Lilly and Company - Revenue by Business Segment (%), 2019
  • Figure 13-16: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segment (%), 2019
  • Figure 13-17: Eli Lilly and Company - Revenue by Geography (%), 2019
  • Figure 13-18: Johnson & Johnson - Revenue by Business Segment (%), 2019
  • Figure 13-19: Johnson & Johnson - Revenue by Pharmaceutical Segment (%), 2019
  • Figure 13-20: Johnson & Johnson - Revenue by Geography (%), 2019
  • Figure 13-21: Amgen Inc. - Revenue by Product (%), 2019
  • Figure 13-22: Amgen Inc. - Revenue by Geography (%), 2019

List of Tables:

  • Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
  • Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
  • Table 6-1: Ongoing Trials for Rituxan
  • Table 6-2: Ongoing Trials for Avastin
  • Table 6-3: Ongoing Trials for Herceptin
  • Table 6-4: Ongoing Trials for ADCETRIS
  • Table 6-5: Ongoing Trials for Kadcyla
  • Table 6-6: Ongoing Trials for Blincyto
  • Table 6-7: Ongoing Trials for Provenge
  • Table 6-8: Ongoing Trials for Yervoy
  • Table 6-9: Ongoing Trials for Opdivo
  • Table 6-10: Ongoing Trials for Keytruda
  • Table 7-1: Global - Oncology Incidence by Geography ('000), 2020 & 2025
  • Table 9-1: Selected Immuno-Oncology and/or Targeted Therapy Combinations
  • Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
  • Table 11-1: Global - Immuno-Oncology Product Pipeline
  • Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2017-2019
  • Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products
  • Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline
  • Table 13-4: Bristol Myers Squibb - Key Financials (Billion US$), 2017-2019
  • Table 13-5: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
  • Table 13-6: Bristol Myers Squibb - Product Pipeline
  • Table 13-7: Merck & Co., Inc. - Key Financials (Billion US$), 2017-2019
  • Table 13-8: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
  • Table 13-9: Merck & Co., Inc. - Product Pipeline
  • Table 13-10: Novartis - Key Financials (Billion US$), 2017-2019
  • Table 13-11: Novartis - Commercialized Immuno-Oncology Products
  • Table 13-12: Novartis - Product Pipeline
  • Table 13-13: AstraZeneca Plc - Key Financials (Billion US$), 2017-2019
  • Table 13-14: AstraZeneca Plc - Commercialized Immuno-Oncology Products
  • Table 13-15: AstraZeneca Plc - Product Pipeline
  • Table 13-16: Pfizer Inc - Key Financials (Billion US$), 2017-2019
  • Table 13-17: Pfizer Inc - Commercialized Immuno-Oncology Products
  • Table 13-18: Pfizer Inc - Product Pipeline
  • Table 13-19: Eli Lilly and Company - Key Financials (Billion US$), 2017-2019
  • Table 13-20: Eli Lilly and Company - Commercialized Immuno-Oncology Products
  • Table 13-21: Eli Lilly and Company - Product Pipeline
  • Table 13-22: Johnson & Johnson - Key Financials (Billion US$), 2017-2019
  • Table 13-23: Johnson & Johnson - Commercialized Immuno-Oncology Products
  • Table 13-24: Johnson & Johnson - Product Pipeline
  • Table 13-25: Amgen Inc. - Key Financials (Billion US$), 2017-2019
  • Table 13-26: Amgen Inc. - Commercialized Immuno-Oncology Products
  • Table 13-27: Amgen Inc. - Product Pipeline
目次

Immuno-oncology is a unique approach that uses the body's immune system to fight cancer. These therapies activate an individual's immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types. The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.

According to the report "Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024", the global immuno-oncology market is anticipated to reach US$ 135 Billion by 2024. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.

The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2019 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).

The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2019, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.

On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2024.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Immuno-Oncology: Overview

4. Market Dynamics

  • 4.1 Drivers
    • 4.1.1 Increasing Cancer Incidences
    • 4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
    • 4.1.3 Growing Geriatric Population
    • 4.1.4 High Healthcare Spending in Developed Economies
    • 4.1.5 Strong Pipeline
    • 4.1.6 Increasing Efficacy in a Wide Variety of Indications
    • 4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
  • 4.2 Challenges
    • 4.2.1 Patent Expiry of Top-Selling Drugs
    • 4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatments
    • 4.2.3 Sky-High Development Costs of Cancer Immunotherapies
    • 4.2.4 High Cost of Treatment
    • 4.2.5 Lack of Awareness
  • 4.3 Opportunities
    • 4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
    • 4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
    • 4.3.3 CAR-T Therapies: The Future of Cancer Care
    • 4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immuno-Oncology Market Outlook 2024

6. Global Immuno-Oncology Market, by Product Class

  • 6.1 Monoclonal Antibodies (mAbs)
    • 6.1.1 Naked Monoclonal Antibodies
      • 6.1.1.1 Rituxan (Rituximab)
      • 6.1.1.2 Avastin (Bevacizumab)
      • 6.1.1.3 Herceptin (Trastuzumab)
    • 6.1.2 Conjugated Monoclonal Antibodies
      • 6.1.2.1 ADCETRIS (Brentuximab vedotin)
      • 6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
    • 6.1.3 Bispecific Monoclonal Antibodies
      • 6.1.3.1 Blincyto (Blinatumomab)
    • 6.1.4 Others
  • 6.2 Therapeutic Vaccines
    • 6.2.1 Provenge
  • 6.3 Immune Checkpoint Inhibitors
    • 6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
      • 6.3.1.1 Yervoy (Ipilimumab)
    • 6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
      • 6.3.2.1 Opdivo (Nivolumab)
      • 6.3.2.2 Keytruda (Pembrolizumab)
  • 6.4 Others

7. Global Immuno-Oncology Market, By Major Indications

  • 7.1 Head & Neck Cancer
  • 7.2 Lung Cancer
  • 7.3 Melanoma
  • 7.4 Lymphoma
  • 7.5 Leukemia
  • 7.6 Others

8. Global Immuno-Oncology Market, By Geography

  • 8.1 North America
  • 8.2 Europe
  • 8.3 Asia-Pacific

9. Trends & Developments

  • 9.1 Lucrative Investment Trend
  • 9.2 Emergence of Targeted and Combination Therapies
  • 9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market

10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry

11. Pipeline Analysis of Immuno-Oncology

12. Competitive Landscape

  • 12.1 Share of Major Players

13. Key Players Analysis

  • 13.1 F. Hoffmann-La Roche AG
  • 13.2 Bristol-Myers Squibb
  • 13.3 Merck & Co., Inc.
  • 13.4 Novartis
  • 13.5 AstraZeneca Plc
  • 13.6 Pfizer Inc
  • 13.7 Eli Lilly and Company
  • 13.8 Johnson & Johnson
  • 13.9 Amgen Inc.
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.